Oncopeptides AB AI Stock Analysis
Want to see SE:ONCO full AI Analyst Report?
Oncopeptides AB (ONCO) AI Stock Analysis
Oncopeptides AB
(Nasdaq OMX AB:ONCO)
The overall score is heavily pressured by the company's precarious financial position, marked by insolvency and significant cash burn, which represents an existential risk. This is partially offset by a very positive earnings call, which highlighted strong commercial momentum for Pepaxti, a near-term catalyst in a label expansion, and a promising new pipeline opportunity in glioblastoma. Technical and valuation metrics remain weak, reflecting the company's current unprofitable state.
Oncopeptides AB (ONCO) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 707.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 5.42M
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 0.12
- Revenue Growth
- 65.37%
- EPS Growth
- 43.28%
- Country
- Sweden
- Employees
- 71
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Oncopeptides AB Business Overview & Revenue Model
Company Description
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate...
Oncopeptides AB Earnings Call Summary
The call was strongly constructive, with accelerating Pepaxti sales, approximately 98% gross margins, lower operating expenses, improved operating leverage, strengthened financing, a positive CHMP opinion for third-line expansion, and positive initial human glioblastoma data. The main negatives were Q3 seasonality, a flat German market, the still-pending European Commission decision, uncertainty around the glioblastoma development path, additional clinical program costs, and the delayed Japanese partnership process. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management remains on track to achieve positive cash flow during 2027, with the cash flow guidance based on European Pepaxti commercial operations becoming self-sustaining; the target was expressed before the third-line opportunity, although third line “will help reach our target ... for sure.” Total operating cost “just below SEK 300 million” is expected to remain a relevant benchmark for the full year 2026, while the commercial part of Oncopeptides is expected to run “more or less on the same cost base” in 2027, excluding additional glioblastoma costs. For Q4, management is not commenting on the current quarter but expects, “granted that nothing really unexpected happens,” the trend to be “more similar to the year before,” with Q4 “commonly stronger than Q3” and “more into the 2024 trend rather than the 2025 trend.” The formal European Commission decision is expected “in the coming weeks,” “no later than 60 days following a CHMP decision,” followed by a German reimbursement dossier “within approximately one month” of a positive decision; glioblastoma development could reach market “rather sooner than later,” with a program “much shorter” than average time to market, including “accelerated approval in the U.S.,” “potential faster approval” in Europe, and “most likely orphan drug designation.”
Oncopeptides AB Financial Statement Overview
Summary
Financial health is critically weak. The income statement shows strong revenue growth and excellent gross margins, but the company is deeply unprofitable. The balance sheet is under severe stress with negative equity, indicating insolvency risk. Cash flow is a major concern, with operating losses translating directly into cash burn, making the company dependent on external financing.
Income Statement
35NegativeBalance Sheet
10Very NegativeCash Flow
30Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 103.50M | 71.12M | 31.65M | 35.22M | 8.36M | 118.30M |
| Gross Profit | 99.90M | 59.00M | 28.98M | 36.30M | 8.35M | 65.17M |
| EBITDA | -180.27M | -219.26M | -261.81M | -231.62M | -319.64M | -1.41B |
| Net Income | -196.04M | -249.59M | -284.61M | -249.11M | -337.95M | -1.43B |
Balance Sheet | ||||||
| Total Assets | 175.87M | 134.84M | 244.19M | 238.38M | 385.32M | 439.38M |
| Cash, Cash Equivalents and Short-Term Investments | 116.84M | 82.25M | 178.54M | 173.44M | 344.51M | 364.30M |
| Total Debt | 140.42M | 139.39M | 141.72M | 126.16M | 9.54M | 14.19M |
| Total Liabilities | 192.37M | 193.73M | 189.91M | 181.60M | 91.03M | 228.51M |
| Stockholders Equity | -16.50M | -58.89M | 54.28M | 56.78M | 294.29M | 210.87M |
Cash Flow | ||||||
| Free Cash Flow | -192.57M | -222.88M | -260.57M | -279.61M | -423.02M | -1.52B |
| Operating Cash Flow | -192.57M | -222.88M | -260.57M | -279.49M | -420.51M | -1.52B |
| Investing Cash Flow | 0 | 0 | 496.00K | -116.00K | -2.51M | -339.00K |
| Financing Cash Flow | 162.95M | 128.55M | 263.81M | 106.89M | 392.40M | 1.03B |
Oncopeptides AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCO, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.91, and below the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.12 is Neutral, neither overbought nor oversold. The STOCH value of 7.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ONCO.
Oncopeptides AB Peers Comparison
Overall Rating
SE:CANTA83Outperform
SE:SPRINT80Outperform
SE:IMMU48Neutral
SE:ONCO47Neutral
SE:ATORX39Underperform
SE:BINV37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | SEK 360.89M | 1.90 | 63.09% | ― | ― | ― | |
| 80Outperform | SEK 400.96M | 5.49 | 71.44% | ― | 170.38% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 217.58M | -1.96 | -19.14% | ― | ― | 13.06% | |
| 47Neutral | SEK 729.43M | -2.60 | ― | ― | 65.37% | 43.28% | |
| 39Underperform | SEK 30.33M | -0.01 | -439.98% | ― | -99.33% | 64.90% | |
| 37Underperform | SEK 142.80M | -0.28 | -128.54% | ― | -83.67% | -50.29% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ONCO | Oncopeptides AB | 1.64 | -3.30 | -66.83% | |
| SE:ATORX | Alligator Bioscience AB | 0.01 | -0.15 | -93.83% | |
| SE:BINV | BioInvent International AB | 2.09 | -27.96 | -93.04% | |
| SE:IMMU | Immunicum AB | 3.50 | -1.49 | -29.79% | |
| SE:CANTA | Cantargia AB | 1.29 | -1.94 | -60.03% | |
| SE:SPRINT | Sprint Bioscience AB | 3.68 | 2.24 | 155.56% |
Oncopeptides AB Corporate Events
EU approves Pepaxti label expansion for third-line multiple myeloma
The European Commission approved an expanded marketing authorization for Oncopeptides’ Pepaxti, allowing its use in adults with multiple myeloma after at least two prior therapies whose disease is refractory to lenalidomide and the latest treatment....
Oncopeptides Reports Strong Pepaxti Growth and Glioblastoma Breakthrough
Oncopeptides reported third-quarter Pepaxti sales of SEK 28.5 million, up 41% year over year, while operating loss narrowed to SEK 36.5 million and cash stood at SEK 116.8 million. Nine-month sales rose 62% to nearly SEK 85 million, and trailing twel...
European real-world data supports Pepaxti in advanced myeloma
Oncopeptides, a biotechnology company focused on difficult-to-treat cancers, said two independent European real-world studies of Pepaxti plus dexamethasone in relapsed, refractory multiple myeloma have been accepted for presentation at ASH 2026. The...
Oncopeptides Boosts Capital Base with Directed Share Issue to Institutional Investors
Oncopeptides AB has increased its number of shares and voting rights following the completion of a directed share issue of 50,000,000 ordinary shares to Swedish and international institutional investors. As of October 30, 2026, the company’s total sh...
Oncopeptides to present Q3 2026 results in investor webcast
Oncopeptides AB has scheduled the publication of its third-quarter 2026 report for November 5 at 08:00 CET, underscoring its effort to maintain transparency with the market. The Stockholm-based biotech, which is focused on therapies for hard-to-treat...
Oncopeptides Raises SEK 100 Million in Discounted Directed Share Issue to Fund Glioblastoma Push
Oncopeptides AB has completed a directed share issue of 50 million new ordinary shares to Swedish and international institutional investors, raising SEK 100 million at a 13.9 percent discount to the latest closing price. The move follows participatio...
Oncopeptides Seeks SEK 100m in Directed Share Issue to Accelerate Glioblastoma Program
Oncopeptides plans a directed share issue of about SEK 100 million to Swedish and international institutional investors, deviating from shareholders’ preferential rights under an existing mandate. The company’s largest shareholder, HealthCap VIII LP,...
Oncopeptides to Brief Investors After Positive Glioblastoma Study Data
Oncopeptides AB, a Stockholm-listed biotech specializing in targeted cancer therapies, has built its business around proprietary Peptide Drug Conjugate technology to deliver cytotoxic agents directly into tumor cells. Its lead oncology product is alr...
Oncopeptides Reports Breakthrough Blood-Brain Barrier Data in Glioblastoma Study
Oncopeptides AB is a Stockholm-based biotech company focused on developing treatments for difficult-to-treat cancers, leveraging its proprietary Peptide Drug Conjugate platform. The firm is listed on Nasdaq Stockholm and is expanding in neuro-oncolog...
Oncopeptides earns EANO poster nod as PDC platform pushes into glioblastoma
Oncopeptides has secured acceptance of three abstracts on its next-generation alkylating peptide-drug conjugates in glioblastoma for presentation at the 2026 European Association of Neuro-Oncology Congress in Rome, marking its first major scientific...
Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting
Oncopeptides AB, a Stockholm-listed biotech focused on hard-to-treat cancers, is using its proprietary peptide-based platforms to develop targeted oncology drugs, led by the multiple myeloma therapy Pepaxti. With commercial rollout underway in Europe...
Oncopeptides Wins EMA Backing to Move Pepaxti Into Third-Line Myeloma Use
Oncopeptides has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use to expand Pepaxti’s label into third-line treatment for adult multiple myeloma patients refractory to lenalidomide and their last therapy. The...
Oncopeptides lifts Q2 sales 62% and moves to double Pepaxti market in Europe
Oncopeptides reported strong commercial momentum in the second quarter of 2026, with net sales rising 62 percent year-on-year to SEK 31.1 million and first-half sales up 74 percent to SEK 56.5 million. Despite an operating loss, the company ended the...
Oncopeptides to Present Q2 2026 Results as Oncology Commercialization Expands
Oncopeptides AB, a Stockholm‑listed biotech focused on targeted cancer therapies, is expanding commercialization of its flagship oncology drug across Europe and select international markets. With proprietary platforms and a lean footprint of around 7...
Oncopeptides Secures Slovenian List Price for Pepaxti in First CEE Expansion Step
Oncopeptides has secured a maximum allowed list price for its multiple myeloma drug Pepaxti in Slovenia, a key reference pricing market in Central and Eastern Europe, establishing a regulatory basis for subsequent market access and reimbursement talk...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
